Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
August 6, 2026 9:56 AM EDTAll IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögrens disease (SjD) and cutaneous lupus erythematosus (CLE)
Current cash balance provides runway to the potential launch of IMVT-1402 in GD
Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026
DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal... More
